204 related articles for article (PubMed ID: 28880238)
1. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
3. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
4. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
5. ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
Trumpi K; Emmink BL; Prins AM; van Oijen MG; van Diest PJ; Punt CJ; Koopman M; Kranenburg O; Rinkes IH
J Cancer; 2015; 6(11):1079-86. PubMed ID: 26516354
[TBL] [Abstract][Full Text] [Related]
6. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Palshof JA; Cederbye CN; Høgdall EVS; Poulsen TS; Linnemann D; Nygaard SB; Stenvang J; Christensen IJ; Jensen BV; Pfeiffer P; Brünner N; Yilmaz M; Viuff BM; Nielsen DL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708825
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Moon HH; Kim SH; Ku JL
Oncol Rep; 2016 Jan; 35(1):298-306. PubMed ID: 26497773
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
10. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
12. Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Cederbye CN; Palshof JA; Hansen TP; Duun-Henriksen AK; Linnemann D; Stenvang J; Nielsen DL; Brünner N; Viuff BM
Sci Rep; 2016 Jun; 6():26997. PubMed ID: 27257141
[TBL] [Abstract][Full Text] [Related]
13. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival.
Wang X; Xia B; Liang Y; Peng L; Wang Z; Zhuo J; Wang W; Jiang B
Cancer Biomark; 2013; 13(2):81-8. PubMed ID: 23838136
[TBL] [Abstract][Full Text] [Related]
14. RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
Ruihua H; Mengyi Z; Chong Z; Meng Q; Xin M; Qiulin T; Feng B; Ming L
Oncotarget; 2016 Dec; 7(52):87136-87146. PubMed ID: 27888624
[TBL] [Abstract][Full Text] [Related]
15. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Katayama R; Koike S; Sato S; Sugimoto Y; Tsuruo T; Fujita N
Cancer Sci; 2009 Nov; 100(11):2060-8. PubMed ID: 19673889
[TBL] [Abstract][Full Text] [Related]
16. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC
Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935
[TBL] [Abstract][Full Text] [Related]
17. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
18. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
20. Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism.
Nie S; Huang Y; Shi M; Qian X; Li H; Peng C; Kong B; Zou X; Shen S
Oncol Rep; 2018 Oct; 40(4):2137-2146. PubMed ID: 30066914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
